Literature DB >> 15793853

Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors.

Mary Pat McAndrews1, Karl Farcnik, Peter Carlen, Andrei Damyanovich, Mirela Mrkonjic, Susan Jones, E Jenny Heathcote.   

Abstract

Neurocognitive morbidity has been reported in individuals with chronic hepatitis C virus (HCV) infection, but the magnitude of such dysfunction in the absence of disease-correlated factors known to affect the central nervous system (e.g., substance abuse, cirrhosis, depression, interferon treatment) and the impact of any such change on functioning is unclear. We investigated a cohort of individuals with HCV, all of whom were carefully screened to exclude relevant comorbidities, to elucidate virus-related changes in the brain using neuropsychological tests and magnetic resonance spectroscopy (MRS). A cohort of 37 patients with chronic HCV infection was culled from 300 consecutive patients presenting to a tertiary care liver clinic. A comparison group of healthy controls (n = 46) was also assessed. Of 10 neurocognitive measures evaluated, the HCV group showed marginally poorer learning efficiency compared with controls; only 13% of patients demonstrated a clinical level of impairment on this test (defined as 1.5 SD below the normative standard). Although patients reported greater levels of fatigue and symptoms of depression, these factors did not correlate with the degree of learning inefficiency. With respect to MRS, the HCV group demonstrated increased choline and reduced N-acetyl aspartate relative to controls in the central white matter. Indicators of liver disease severity did not correlate with either memory or MRS abnormalities. In conclusion, while our findings support an association between hepatitis C and indicators of central nervous system involvement in a cohort of patients carefully screened to eliminate other factors influencing neurocognitive integrity, the clinical significance of these effects is limited.

Entities:  

Mesh:

Year:  2005        PMID: 15793853     DOI: 10.1002/hep.20635

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

1.  Clinical contributors to cerebral white matter integrity in HIV-infected individuals.

Authors:  Assawin Gongvatana; Ronald A Cohen; Stephen Correia; Kathryn N Devlin; Jadrian Miles; Hakmook Kang; Hernando Ombao; Bradford Navia; David H Laidlaw; Karen T Tashima
Journal:  J Neurovirol       Date:  2011-10-01       Impact factor: 2.643

Review 2.  Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction: a neuroimmunologial condition?

Authors:  D M Forton
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

3.  Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.

Authors:  Jeng-Fu Yang; Yi-Hui Kao; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2010-08-09       Impact factor: 6.047

4.  Intra-individual variability across neurocognitive domains in chronic hepatitis C infection: elevated dispersion is associated with serostatus and unemployment risk.

Authors:  Erin E Morgan; Steven Paul Woods; Alexandra Rooney; William Perry; Igor Grant; Scott L Letendre
Journal:  Clin Neuropsychol       Date:  2012-04-26       Impact factor: 3.535

Review 5.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

6.  Cognitive impairment in hepatitis C patients on antiviral therapy.

Authors:  Jessica Irwin; Norah Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

Review 7.  Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.

Authors:  Linda Chang; Sody M Munsaka; Stephanie Kraft-Terry; Thomas Ernst
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-12       Impact factor: 4.147

8.  Improvements in brain and behavior following eradication of hepatitis C.

Authors:  Taylor Kuhn; Philip Sayegh; Jacob D Jones; Jason Smith; Manoj K Sarma; A Ragin; Elyse J Singer; M Albert Thomas; April D Thames; Steven A Castellon; Charles H Hinkin
Journal:  J Neurovirol       Date:  2017-05-30       Impact factor: 2.643

Review 9.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 10.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.